CorMedix Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
CorMedix announced FDA acceptance for Priority Review of a supplemental NDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease in adults undergoing allogeneic HSCT, with PDUFA target action date in Q1 2027. The sNDA is supported by positive Phase III ReSPECT topline results announced in April. If approved, the company targets promotional launch in H2 2027. Mundipharma is the global development partner and submitter of the application.
Why this rating
Priority Review acceptance is material regulatory progress for a ~$910M biotech; new indication could expand addressable market meaningfully. Not yet approved, so execution risk remains.
Price action (we called it positive)
before filing · preread $7.45 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.